The Nocebo Effect in a Non-Medical Switching Program from Originator to Biosimilar Infliximab in Inflammatory Bowel Disease
Krishneel Dutt, Ashish Srinivasan, Daniel R. van Langenberg
Topics & Concepts
MedicineBiosimilarInfliximabInflammatory bowel diseaseNocebo EffectVisual analogue scaleCohortInternal medicineNoceboUlcerative colitisDiseasePhysical therapyPlaceboPathologyAlternative medicineBiosimilars and Bioanalytical MethodsPharmacogenetics and Drug MetabolismHealthcare cost, quality, practices